Efficacy of guselkumab in a subpopulation with pustulotic arthro‐osteitis through week 52: an exploratory analysis of a phase 3, randomized, double‐blind, placebo‐controlled study in Japanese patients with palmoplantar pustulosis
Background Previous studies of guselkumab have demonstrated clinical benefits in patients with plaque‐type psoriasis, generalized pustular psoriasis, erythrodermic psoriasis and palmoplantar pustulosis (PPP). Objective The aim of this exploratory analysis of a double‐blind, multicenter, placebo‐cont...
Gespeichert in:
| Veröffentlicht in: | Journal of the European Academy of Dermatology and Venereology 2020-10, Vol.34 (10), p.2318-2329 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2329 |
|---|---|
| container_issue | 10 |
| container_start_page | 2318 |
| container_title | Journal of the European Academy of Dermatology and Venereology |
| container_volume | 34 |
| creator | Yamamoto, T. Fukuda, K. Morita, A. Kimura, T. Morishima, H. Goto, R. Zheng, R. Terui, T. |
| description | Background
Previous studies of guselkumab have demonstrated clinical benefits in patients with plaque‐type psoriasis, generalized pustular psoriasis, erythrodermic psoriasis and palmoplantar pustulosis (PPP).
Objective
The aim of this exploratory analysis of a double‐blind, multicenter, placebo‐controlled, phase 3 study in Japanese patients with PPP was to evaluate the efficacy of guselkumab in the subset of patients with pustulotic arthro‐osteitis (PAO).
Methods
Patients were randomized to receive guselkumab 100 or 200 mg at weeks 0, 4, 12 and every 8 weeks, or placebo with cross‐over to guselkumab 100 or 200 mg at week 16 (placebo group). Efficacy endpoints were changes from baseline in magnetic resonance imaging (MRI) score, EuroQOL‐5 dimensions (EQ‐5D) index score, EQ‐5D pain/discomfort dimension score and C‐reactive protein (CRP, mg/L) level in all PAO patients through week 52. Data from both guselkumab groups were combined and presented as results for a single overall guselkumab group.
Results
Among 159 patients with PPP, 66 with PAO were randomized across treatment groups. For patients with MRI data for all regions assessed, the proportion of patients in the guselkumab group with PAO characterized as severe decreased from 23.8% (10/42) at baseline to 5.4% (2/42) at week 52. The mean (SD) change from baseline at week 52 in EQ‐5D index score was 0.20 (0.17) among PPP patients with PAO and 0.15 (0.17) among those without PAO in the guselkumab group. Among all PAO patients, the proportions with an EQ‐5D pain/discomfort dimension score of no or slight pain/discomfort in the guselkumab group increased from baseline to week 52 [33.3% (7/21) vs. 87.5% (35/40)]. The mean (SD) CRP levels decreased in all PAO patients in the guselkumab group at week 52 compared to baseline [−1.71 (8.16) mg/L].
Conclusion
Guselkumab treatment showed beneficial outcomes for PAO signs and symptoms in Japanese patients with PPP. |
| doi_str_mv | 10.1111/jdv.16355 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1111_jdv_16355</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2377678099</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4155-d41f170f68cf14463181910f25dbe2d9be080f7db5f270e103e29ef9eda674623</originalsourceid><addsrcrecordid>eNqNks1u1DAUhSMEokNhwQsgL0F0WjuJk5gFEhrKT1WJDbCNHPt6xq0TB_90CCsegWdk25eopzMdwQIJb6wrf_fc46uTZU8JPibpnFzIq2NSFZTey2akrJp5gZvifjbDLK_mjFF2kD3y_gJjTAhtHmYHRU7qgpFqll2fKqUFFxOyCi2jB3MZe94hPSCOfOxGO0bDg7YDWuuwQmP0IRobtEDchZWzv3_-sj6ADtqjTR2XK7QGuEQ0f4X4gOD7aKzjwbopldxMPoFpFkfjintAxRFyfJC21z9AHiFpY2cgiXZGD6keDRfQbaYIOwRnjQGJkgU5bSye8ZEPkFTGZBGG4Hcmuelt6hwCd3eO09jH2QPFjYcnu_sw-_Lu9PPiw_z80_uPizfnc1ESSueyJIrUWFWNUKQsq4I0hBGscio7yCXrADdY1bKjKq8xEFxAzkAxkLyqyyovDrPXW90xdj1IkYw5btrR6Z67qbVct3-_DHrVLu1VW9OmYk2VBJ7vBJz9FsGHttdegEk_Aht9mxd1XdUNZiyhL7aocNZ7B2o_huB2E442haO9DUdin_3pa0_epSEBzRZYp5UrL9JKBeyxFB9a5A1leHPIQofbXCxsHEJqffn_rYk-2dHawPRvy-3Z269b7zfHb--q</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2377678099</pqid></control><display><type>article</type><title>Efficacy of guselkumab in a subpopulation with pustulotic arthro‐osteitis through week 52: an exploratory analysis of a phase 3, randomized, double‐blind, placebo‐controlled study in Japanese patients with palmoplantar pustulosis</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><source>Web of Science - Science Citation Index Expanded - 2020<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /></source><creator>Yamamoto, T. ; Fukuda, K. ; Morita, A. ; Kimura, T. ; Morishima, H. ; Goto, R. ; Zheng, R. ; Terui, T.</creator><creatorcontrib>Yamamoto, T. ; Fukuda, K. ; Morita, A. ; Kimura, T. ; Morishima, H. ; Goto, R. ; Zheng, R. ; Terui, T.</creatorcontrib><description>Background
Previous studies of guselkumab have demonstrated clinical benefits in patients with plaque‐type psoriasis, generalized pustular psoriasis, erythrodermic psoriasis and palmoplantar pustulosis (PPP).
Objective
The aim of this exploratory analysis of a double‐blind, multicenter, placebo‐controlled, phase 3 study in Japanese patients with PPP was to evaluate the efficacy of guselkumab in the subset of patients with pustulotic arthro‐osteitis (PAO).
Methods
Patients were randomized to receive guselkumab 100 or 200 mg at weeks 0, 4, 12 and every 8 weeks, or placebo with cross‐over to guselkumab 100 or 200 mg at week 16 (placebo group). Efficacy endpoints were changes from baseline in magnetic resonance imaging (MRI) score, EuroQOL‐5 dimensions (EQ‐5D) index score, EQ‐5D pain/discomfort dimension score and C‐reactive protein (CRP, mg/L) level in all PAO patients through week 52. Data from both guselkumab groups were combined and presented as results for a single overall guselkumab group.
Results
Among 159 patients with PPP, 66 with PAO were randomized across treatment groups. For patients with MRI data for all regions assessed, the proportion of patients in the guselkumab group with PAO characterized as severe decreased from 23.8% (10/42) at baseline to 5.4% (2/42) at week 52. The mean (SD) change from baseline at week 52 in EQ‐5D index score was 0.20 (0.17) among PPP patients with PAO and 0.15 (0.17) among those without PAO in the guselkumab group. Among all PAO patients, the proportions with an EQ‐5D pain/discomfort dimension score of no or slight pain/discomfort in the guselkumab group increased from baseline to week 52 [33.3% (7/21) vs. 87.5% (35/40)]. The mean (SD) CRP levels decreased in all PAO patients in the guselkumab group at week 52 compared to baseline [−1.71 (8.16) mg/L].
Conclusion
Guselkumab treatment showed beneficial outcomes for PAO signs and symptoms in Japanese patients with PPP.</description><identifier>ISSN: 0926-9959</identifier><identifier>EISSN: 1468-3083</identifier><identifier>DOI: 10.1111/jdv.16355</identifier><identifier>PMID: 32173916</identifier><language>eng</language><publisher>HOBOKEN: Wiley</publisher><subject>Antibodies, Monoclonal, Humanized ; Dermatology ; Double-Blind Method ; Humans ; Japan ; Life Sciences & Biomedicine ; Original ; Osteitis ; Psoriasis ; Psoriasis - drug therapy ; Science & Technology ; Severity of Illness Index</subject><ispartof>Journal of the European Academy of Dermatology and Venereology, 2020-10, Vol.34 (10), p.2318-2329</ispartof><rights>2020 Janssen Pharmaceutical K.K. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology</rights><rights>2020 Janssen Pharmaceutical K.K. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>17</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wos000532859000001</woscitedreferencesoriginalsourcerecordid><citedby>FETCH-LOGICAL-c4155-d41f170f68cf14463181910f25dbe2d9be080f7db5f270e103e29ef9eda674623</citedby><cites>FETCH-LOGICAL-c4155-d41f170f68cf14463181910f25dbe2d9be080f7db5f270e103e29ef9eda674623</cites><orcidid>0000-0002-2903-4920</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fjdv.16355$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fjdv.16355$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>230,315,782,786,887,1419,27931,27932,28255,45581,45582</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32173916$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yamamoto, T.</creatorcontrib><creatorcontrib>Fukuda, K.</creatorcontrib><creatorcontrib>Morita, A.</creatorcontrib><creatorcontrib>Kimura, T.</creatorcontrib><creatorcontrib>Morishima, H.</creatorcontrib><creatorcontrib>Goto, R.</creatorcontrib><creatorcontrib>Zheng, R.</creatorcontrib><creatorcontrib>Terui, T.</creatorcontrib><title>Efficacy of guselkumab in a subpopulation with pustulotic arthro‐osteitis through week 52: an exploratory analysis of a phase 3, randomized, double‐blind, placebo‐controlled study in Japanese patients with palmoplantar pustulosis</title><title>Journal of the European Academy of Dermatology and Venereology</title><addtitle>J EUR ACAD DERMATOL</addtitle><addtitle>J Eur Acad Dermatol Venereol</addtitle><description>Background
Previous studies of guselkumab have demonstrated clinical benefits in patients with plaque‐type psoriasis, generalized pustular psoriasis, erythrodermic psoriasis and palmoplantar pustulosis (PPP).
Objective
The aim of this exploratory analysis of a double‐blind, multicenter, placebo‐controlled, phase 3 study in Japanese patients with PPP was to evaluate the efficacy of guselkumab in the subset of patients with pustulotic arthro‐osteitis (PAO).
Methods
Patients were randomized to receive guselkumab 100 or 200 mg at weeks 0, 4, 12 and every 8 weeks, or placebo with cross‐over to guselkumab 100 or 200 mg at week 16 (placebo group). Efficacy endpoints were changes from baseline in magnetic resonance imaging (MRI) score, EuroQOL‐5 dimensions (EQ‐5D) index score, EQ‐5D pain/discomfort dimension score and C‐reactive protein (CRP, mg/L) level in all PAO patients through week 52. Data from both guselkumab groups were combined and presented as results for a single overall guselkumab group.
Results
Among 159 patients with PPP, 66 with PAO were randomized across treatment groups. For patients with MRI data for all regions assessed, the proportion of patients in the guselkumab group with PAO characterized as severe decreased from 23.8% (10/42) at baseline to 5.4% (2/42) at week 52. The mean (SD) change from baseline at week 52 in EQ‐5D index score was 0.20 (0.17) among PPP patients with PAO and 0.15 (0.17) among those without PAO in the guselkumab group. Among all PAO patients, the proportions with an EQ‐5D pain/discomfort dimension score of no or slight pain/discomfort in the guselkumab group increased from baseline to week 52 [33.3% (7/21) vs. 87.5% (35/40)]. The mean (SD) CRP levels decreased in all PAO patients in the guselkumab group at week 52 compared to baseline [−1.71 (8.16) mg/L].
Conclusion
Guselkumab treatment showed beneficial outcomes for PAO signs and symptoms in Japanese patients with PPP.</description><subject>Antibodies, Monoclonal, Humanized</subject><subject>Dermatology</subject><subject>Double-Blind Method</subject><subject>Humans</subject><subject>Japan</subject><subject>Life Sciences & Biomedicine</subject><subject>Original</subject><subject>Osteitis</subject><subject>Psoriasis</subject><subject>Psoriasis - drug therapy</subject><subject>Science & Technology</subject><subject>Severity of Illness Index</subject><issn>0926-9959</issn><issn>1468-3083</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><sourceid>AOWDO</sourceid><sourceid>EIF</sourceid><recordid>eNqNks1u1DAUhSMEokNhwQsgL0F0WjuJk5gFEhrKT1WJDbCNHPt6xq0TB_90CCsegWdk25eopzMdwQIJb6wrf_fc46uTZU8JPibpnFzIq2NSFZTey2akrJp5gZvifjbDLK_mjFF2kD3y_gJjTAhtHmYHRU7qgpFqll2fKqUFFxOyCi2jB3MZe94hPSCOfOxGO0bDg7YDWuuwQmP0IRobtEDchZWzv3_-sj6ADtqjTR2XK7QGuEQ0f4X4gOD7aKzjwbopldxMPoFpFkfjintAxRFyfJC21z9AHiFpY2cgiXZGD6keDRfQbaYIOwRnjQGJkgU5bSye8ZEPkFTGZBGG4Hcmuelt6hwCd3eO09jH2QPFjYcnu_sw-_Lu9PPiw_z80_uPizfnc1ESSueyJIrUWFWNUKQsq4I0hBGscio7yCXrADdY1bKjKq8xEFxAzkAxkLyqyyovDrPXW90xdj1IkYw5btrR6Z67qbVct3-_DHrVLu1VW9OmYk2VBJ7vBJz9FsGHttdegEk_Aht9mxd1XdUNZiyhL7aocNZ7B2o_huB2E442haO9DUdin_3pa0_epSEBzRZYp5UrL9JKBeyxFB9a5A1leHPIQofbXCxsHEJqffn_rYk-2dHawPRvy-3Z269b7zfHb--q</recordid><startdate>202010</startdate><enddate>202010</enddate><creator>Yamamoto, T.</creator><creator>Fukuda, K.</creator><creator>Morita, A.</creator><creator>Kimura, T.</creator><creator>Morishima, H.</creator><creator>Goto, R.</creator><creator>Zheng, R.</creator><creator>Terui, T.</creator><general>Wiley</general><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>WIN</scope><scope>AOWDO</scope><scope>BLEPL</scope><scope>DTL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-2903-4920</orcidid></search><sort><creationdate>202010</creationdate><title>Efficacy of guselkumab in a subpopulation with pustulotic arthro‐osteitis through week 52: an exploratory analysis of a phase 3, randomized, double‐blind, placebo‐controlled study in Japanese patients with palmoplantar pustulosis</title><author>Yamamoto, T. ; Fukuda, K. ; Morita, A. ; Kimura, T. ; Morishima, H. ; Goto, R. ; Zheng, R. ; Terui, T.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4155-d41f170f68cf14463181910f25dbe2d9be080f7db5f270e103e29ef9eda674623</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Antibodies, Monoclonal, Humanized</topic><topic>Dermatology</topic><topic>Double-Blind Method</topic><topic>Humans</topic><topic>Japan</topic><topic>Life Sciences & Biomedicine</topic><topic>Original</topic><topic>Osteitis</topic><topic>Psoriasis</topic><topic>Psoriasis - drug therapy</topic><topic>Science & Technology</topic><topic>Severity of Illness Index</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yamamoto, T.</creatorcontrib><creatorcontrib>Fukuda, K.</creatorcontrib><creatorcontrib>Morita, A.</creatorcontrib><creatorcontrib>Kimura, T.</creatorcontrib><creatorcontrib>Morishima, H.</creatorcontrib><creatorcontrib>Goto, R.</creatorcontrib><creatorcontrib>Zheng, R.</creatorcontrib><creatorcontrib>Terui, T.</creatorcontrib><collection>Wiley Online Library (Open Access Collection)</collection><collection>Wiley Online Library (Open Access Collection)</collection><collection>Web of Science - Science Citation Index Expanded - 2020</collection><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of the European Academy of Dermatology and Venereology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yamamoto, T.</au><au>Fukuda, K.</au><au>Morita, A.</au><au>Kimura, T.</au><au>Morishima, H.</au><au>Goto, R.</au><au>Zheng, R.</au><au>Terui, T.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy of guselkumab in a subpopulation with pustulotic arthro‐osteitis through week 52: an exploratory analysis of a phase 3, randomized, double‐blind, placebo‐controlled study in Japanese patients with palmoplantar pustulosis</atitle><jtitle>Journal of the European Academy of Dermatology and Venereology</jtitle><stitle>J EUR ACAD DERMATOL</stitle><addtitle>J Eur Acad Dermatol Venereol</addtitle><date>2020-10</date><risdate>2020</risdate><volume>34</volume><issue>10</issue><spage>2318</spage><epage>2329</epage><pages>2318-2329</pages><issn>0926-9959</issn><eissn>1468-3083</eissn><abstract>Background
Previous studies of guselkumab have demonstrated clinical benefits in patients with plaque‐type psoriasis, generalized pustular psoriasis, erythrodermic psoriasis and palmoplantar pustulosis (PPP).
Objective
The aim of this exploratory analysis of a double‐blind, multicenter, placebo‐controlled, phase 3 study in Japanese patients with PPP was to evaluate the efficacy of guselkumab in the subset of patients with pustulotic arthro‐osteitis (PAO).
Methods
Patients were randomized to receive guselkumab 100 or 200 mg at weeks 0, 4, 12 and every 8 weeks, or placebo with cross‐over to guselkumab 100 or 200 mg at week 16 (placebo group). Efficacy endpoints were changes from baseline in magnetic resonance imaging (MRI) score, EuroQOL‐5 dimensions (EQ‐5D) index score, EQ‐5D pain/discomfort dimension score and C‐reactive protein (CRP, mg/L) level in all PAO patients through week 52. Data from both guselkumab groups were combined and presented as results for a single overall guselkumab group.
Results
Among 159 patients with PPP, 66 with PAO were randomized across treatment groups. For patients with MRI data for all regions assessed, the proportion of patients in the guselkumab group with PAO characterized as severe decreased from 23.8% (10/42) at baseline to 5.4% (2/42) at week 52. The mean (SD) change from baseline at week 52 in EQ‐5D index score was 0.20 (0.17) among PPP patients with PAO and 0.15 (0.17) among those without PAO in the guselkumab group. Among all PAO patients, the proportions with an EQ‐5D pain/discomfort dimension score of no or slight pain/discomfort in the guselkumab group increased from baseline to week 52 [33.3% (7/21) vs. 87.5% (35/40)]. The mean (SD) CRP levels decreased in all PAO patients in the guselkumab group at week 52 compared to baseline [−1.71 (8.16) mg/L].
Conclusion
Guselkumab treatment showed beneficial outcomes for PAO signs and symptoms in Japanese patients with PPP.</abstract><cop>HOBOKEN</cop><pub>Wiley</pub><pmid>32173916</pmid><doi>10.1111/jdv.16355</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0002-2903-4920</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0926-9959 |
| ispartof | Journal of the European Academy of Dermatology and Venereology, 2020-10, Vol.34 (10), p.2318-2329 |
| issn | 0926-9959 1468-3083 |
| language | eng |
| recordid | cdi_crossref_primary_10_1111_jdv_16355 |
| source | MEDLINE; Access via Wiley Online Library; Web of Science - Science Citation Index Expanded - 2020<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /> |
| subjects | Antibodies, Monoclonal, Humanized Dermatology Double-Blind Method Humans Japan Life Sciences & Biomedicine Original Osteitis Psoriasis Psoriasis - drug therapy Science & Technology Severity of Illness Index |
| title | Efficacy of guselkumab in a subpopulation with pustulotic arthro‐osteitis through week 52: an exploratory analysis of a phase 3, randomized, double‐blind, placebo‐controlled study in Japanese patients with palmoplantar pustulosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-04T14%3A04%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20of%20guselkumab%20in%20a%20subpopulation%20with%20pustulotic%20arthro%E2%80%90osteitis%20through%20week%2052:%20an%20exploratory%20analysis%20of%20a%20phase%203,%20randomized,%20double%E2%80%90blind,%20placebo%E2%80%90controlled%20study%20in%20Japanese%20patients%20with%20palmoplantar%20pustulosis&rft.jtitle=Journal%20of%20the%20European%20Academy%20of%20Dermatology%20and%20Venereology&rft.au=Yamamoto,%20T.&rft.date=2020-10&rft.volume=34&rft.issue=10&rft.spage=2318&rft.epage=2329&rft.pages=2318-2329&rft.issn=0926-9959&rft.eissn=1468-3083&rft_id=info:doi/10.1111/jdv.16355&rft_dat=%3Cproquest_cross%3E2377678099%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2377678099&rft_id=info:pmid/32173916&rfr_iscdi=true |